Optic Neuritis In the Era of Biomarkers.

[1]  S. Vukusic,et al.  Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease , 2019, Journal of Neuroinflammation.

[2]  M. Bach,et al.  Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? , 2019, Neurology: Neuroimmunology & Neuroinflammation.

[3]  Jacqueline Palace,et al.  Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. , 2019, The New England journal of medicine.

[4]  C. Fraser,et al.  Do Myelin Oligodendrocyte Glycoprotein Antibodies Represent a Distinct Syndrome? , 2019, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[5]  K. Tyler,et al.  Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody , 2019, JAMA neurology.

[6]  M. Reindl,et al.  Myelin oligodendrocyte glycoprotein antibodies in neurological disease , 2018, Nature Reviews Neurology.

[7]  B. Weinshenker,et al.  Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG–Associated Disorders , 2018, JAMA neurology.

[8]  B. Weinshenker,et al.  Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. , 2018, American journal of ophthalmology.

[9]  F. Paul,et al.  Apheresis therapies for NMOSD attacks , 2018, Neurology(R) neuroimmunology & neuroinflammation.

[10]  J. A. Fraser,et al.  Effect of Treating Acute Optic Neuritis With Bioequivalent Oral vs Intravenous Corticosteroids: A Randomized Clinical Trial , 2018, JAMA neurology.

[11]  Jacqueline Palace,et al.  MOG encephalomyelitis: international recommendations on diagnosis and antibody testing , 2018, Journal of Neuroinflammation.

[12]  B. Weinshenker,et al.  Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. , 2018, Ophthalmology.

[13]  O. Ciccarelli,et al.  Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease , 2018, JAMA neurology.

[14]  W. Brück,et al.  Defining distinct features of anti-MOG antibody associated central nervous system demyelination , 2018, Therapeutic advances in neurological disorders.

[15]  F. Paul,et al.  MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature , 2018, Journal of Neuroinflammation.

[16]  A. Maia,et al.  Neuromyelitis Optica Spectrum Disorders: Spectrum of MR Imaging Findings and Their Differential Diagnosis. , 2018, Radiographics : a review publication of the Radiological Society of North America, Inc.

[17]  Jacqueline Palace,et al.  Clinical presentation and prognosis in MOG-antibody disease: a UK study , 2017, Brain : a journal of neurology.

[18]  V. Fung,et al.  Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[19]  F. Paul,et al.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome , 2016, Journal of Neuroinflammation.

[20]  F. Paul,et al.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin , 2016, Journal of Neuroinflammation.

[21]  B. Ertl-Wagner,et al.  Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[22]  F. Paul,et al.  Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case , 2016, Multiple sclerosis.

[23]  C. Lucchinetti,et al.  Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin‐4 channelopathies: a decade later , 2016, Annals of the New York Academy of Sciences.

[24]  H. Abboud,et al.  Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange , 2016, Multiple sclerosis.

[25]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[26]  V. Lennon,et al.  Aquaporin-4 autoimmunity , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[27]  T. Nakazawa,et al.  MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[28]  A. Straube,et al.  Histopathology and clinical course of MOG-antibody-associated encephalomyelitis , 2015, Annals of clinical and translational neurology.

[29]  M. Papadopoulos,et al.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies , 2014, Nature Reviews Neurology.

[30]  Y. Itoyama,et al.  The Pathology of an Autoimmune Astrocytopathy: Lessons Learned from Neuromyelitis Optica , 2014, Brain pathology.

[31]  F. Paul,et al.  Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS) , 2013, Journal of Neurology.

[32]  Jacqueline Palace,et al.  Serologic diagnosis of NMO , 2012, Neurology.

[33]  P. Cabre,et al.  Plasma Exchange in Severe Attacks of Neuromyelitis Optica , 2012, Multiple sclerosis international.

[34]  F. Paul,et al.  Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis , 2010, Journal of the Neurological Sciences.

[35]  Melvin Greer,et al.  Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. , 2008, Archives of neurology.

[36]  Lawrence Steinman,et al.  How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis , 2006, Annals of neurology.

[37]  A. Verkman,et al.  The Journal of Experimental Medicine CORRESPONDENCE , 2005 .

[38]  Ichiro Nakashima,et al.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis , 2004, The Lancet.

[39]  H. Ulmer,et al.  Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. , 2003, The New England journal of medicine.

[40]  D. Kaufman,et al.  Practice parameter: The role of corticosteroids in the management of acute monosymptomatic optic neuritis , 2000, Neurology.

[41]  R. Beck,et al.  What we have learned from the Optic Neuritis Treatment Trial. , 1995, Ophthalmology.

[42]  Neil R. Miller,et al.  A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis , 1992 .